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A

clinical trials supported by the US National Institutes
of Health (NIH) (3). This decision, if sustained, would
greatly limit and delay availability of aducanumab to
patients who could benefit from treatment. This decision
has many foreseeable adverse consequences. The draft
proposal must be understood in the context of the
available efficacy data and the process of accelerated
approval. These are discussed here followed by a
description of the CMS proposal to limit the coverage
of aducanumab to participants in trials. The proposed
CED is not in the best interest of patients with early AD
or the field of AD treatment development. The current
decision is a draft of the proposed CED and is subject
to change until a final decision is rendered on April
11th, 2022. Public comment on the decision is invited
until February 10, 2022, and there is an opportunity to
modify this draft determination (https://www.cms.gov/
medicare-coverage-database/search.aspx).

ducanumab (Aduhelm ) was approved
by the United States (US) Food and Drug
Administration (FDA) for the treatment of
Alzheimer ’s disease on June 7, 2021. Soon after, the
approved labeling was adjusted to direct treatment to
mild cognitive impairment (MCI) due to Alzheimer ’s
disease (AD) and mild AD dementia reflecting the
severity of cognitive impairment among participants in
the clinical trials that led to the approval (1, 2).
Individuals over age 65 in the US are entitled to have
the cost of prescription drugs partially paid by the Center
for Medicare and Medicaid Services (CMS; “Medicare”)
if they participate in an approved insurance plan. Most
people pay a monthly fee for this benefit. When a new
agent becomes available it may be subject to a National
Coverage Determination (NCD) to ascertain if CMS
will pay for the drug and under what circumstances.
CMS covers drugs that are considered “reasonable and
necessary” for the treatment of an illness. The covered
treatment must be shown to meaningfully improve health
outcomes. The NCD process can lead to approval of
coverage, denial for coverage, or limited coverage (3).
On January 11, 2022, Medicare Issued its draft NCD
on Coverage with Evidence Development (CED) for
aducanumab which limits coverage to patients
participating in CMS-approved randomized controlled
TM

Aducanumab
Background
Aducanumab is an anti-amyloid IgG1 monoclonal
antibody (mAb) directed to the N-terminus of the
amyloid beta peptide (Aß) occurring in aggregates (5).

Figure 1. History of aducanumab from laboratory discovery through clinical trials, regulatory review, and CMS
coverage decisions

Trial dates are those derived from clinicaltrials.gov. BLA – Biologics License Application; CED – Coverage with Evidence Determination; CMS – Center for Medicare
and Medicaid Services; FDA – Food and Drug Administration; LTE – Long Term Extension; NCD – National Coverage Determination (illustrator M de la Flor, PhD; © J
Cummings, 2022).
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Nonclinical studies showed that antibody administration
led to marked lowering of brain Aß plaques in animal
models of AD (4). Figure 1 summarizes the history of the
development of aducanumab.

Scale – cognitive subscale (ADAS-cog), and 40% on the
Alzheimer ’s Disease Cooperative Study Activities of
Daily Living Mild Cognitive Impairment version (ADCSADL-MCI). An exploratory assessment of behavioral
changes using the Neuropsychiatric Inventory (NPI)
showed an 87% drug-placebo difference in favor of
aducanumab. There was significant dose-dependent
lowering of brain amyloid evident at week 26 which
was more marked at week 78. Significant reductions
in cerebrospinal fluid (CSF) phospho-tau (p-tau) and
total tau (t-tau) were observed in participants of the CSF
substudy (N = 78). Slowing of decline on the CDR-SB
was correlated with reduction of brain amyloid. Primary
and secondary outcomes of the ENGAGE study showed
no drug-placebo differences. Amyloid reduction in
ENGAGE was somewhat less than observed in EMERGE.
There was a lower cumulative exposure to aducanumab
in the ENGAGE study and fewer patients who received
the high dose of 10 mg/kg for the planned period of
treatment (22% in ENGAGE, 29% in EMERGE). These
dose discrepancies may partially explain the difference in
outcomes of the EMERGE and ENGAGE trials. Patients
who had at least eight consecutive doses of 10 mg/kg
in ENGAGE had a similar slowing of decline to that
observed in EMERGE.
The 22% slowing on the primary outcome has
been challenged as inappropriately small to warrant
the treatment. Slowing by this amount translates to
approximately one additional year in the typical 5-year
period in the MCI stage of AD prior to entering the
terminal dementia phase of the illness; patients should be
empowered to decide if this degree of slowing is desirable
for them.

Efficacy
The first clinical trial of aducanumab was the PRIME
study, a Phase 1B dose-finding trial (5). Participants
shown to have brain amyloid consistent with AD using
amyloid positron emission tomography (PET) received
1, 3, 6, or 10 mg/kg for 12 months. Time- and dosedependent reduction of brain amyloid was observed
on amyloid PET in the 3, 6, and 10 mg/kg dose groups.
Patients in the 6 and 10 mg dose cohorts reached brain
amyloid levels near those considered to be normal at
the end of the trial. The study was not powered for
clinical outcomes. The Clinical Dementia Rating – Sum of
Boxes (CDR-SB) and the Mini Mental State Examination
(MMSE) showed nominally significantly less decline in
the 10 mg/kg dose group than the placebo group; the
Neuropsychological Test Battery and Free and Cued
Selective Reminding Test showed no drug-placebo
difference. A correlation was observed between amyloid
lowering as measured by the amyloid PET composite
standardized update value ratio (SUVR) and the CDR-SB.
On the basis of the PRIME observations, two identical
Phase 3 trials --- ENGAGE and EMERGE --- with 1643
planned participants each were launched (6). The results
of these studies have not been published and the data
discussed here are derived from the comprehensive
presentations of information to the FDA (8). Participants
had early AD confirmed by amyloid PET and had MMSE
scores of 24-30. ENGAGE was launched and began
participant recruitment before EMERGE. Patients were
randomized to a high dose, low dose, or placebo. Low
dose was 3 mg/kg for apolipoprotein E ε4 (APOE4)
gene carriers and 6 mg/kg for APOE4 noncarriers based
on knowledge of the increased risk of amyloid related
imaging abnormalities (ARIA) in those with an APOE4
gene. High dose was 10 mg/kg for participants without
an APOE4 gene and 6 mg/kg for those who had the
APOE4 gene. After trial initiation, a protocol amendment
allowed the high dose to be increased to 10 mg/kg in the
APOE4 gene carriers. A futility analysis of pooled data
from the two trials conducted when half of the patients
had received 18 months of treatment indicated that
the conditional probability of success was low, and the
trials were terminated. The final analyses of the blinded
data of the intent-to-treat population revealed that the
high dose arm of the EMERGE trial met its prespecified
primary outcome (CDR-SB) and ENGAGE did not. All
prespecified secondary outcomes of EMERGE showed
a significant drug-placebo difference. Compared to
placebo, the high dose treatment was associated with
22% slowing of decline on the CDR-SB, 18% on the
MMSE, 27% on the Alzheimer ’s Disease Assessment

Safety
ARIA of the effusion type (ARIA-E) and of the
hemorrhagic type (ARIA-H) were observed in trials of
aducanumab (6, 7). In pooled EMERGE and ENGAGE
studies, ARIA-E was observed in 35% of patients
receiving high dose aducanumab; 14.5% had severe
ARIA-E and 6.1% discontinued trial participation because
of ARIA-E. The frequency of ARIA-E was higher in those
with at least one copy of the APOE4 gene (43%). Among
participants with high dose exposure, 19.1% had ARIA-H,
and 14.6% had superficial siderosis consistent with
hemosiderin deposits resulting from hemorrhage into the
brain parenchyma or on the pial surface. Most ARIA-E
(74%) produced no symptoms.

Summary
The irregular aspects of the trials of aducanumab with
premature termination suggest caution in interpreting the
results. The consistent pharmacodynamic relationships
among dose, duration, amyloid lowering, and slowing
of clinical decline (as seen on the CDR-SB) support the
2
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efficacy of aducanumab. The effect on “downstream”
biomarkers (p-tau, t-tau) associated with cognitive
decline in many studies is additional evidence of the
impact of aducanumab on the biology of AD and disease
modification (8). An efficacy conclusion for anti-amyloid
mAbs is consistent with observations emerging from
studies of other agents in this class (discussed below).

biology of the therapeutic response or is a marker for
an effect on toxic amyloid oligomers, tau species, or
inflammation remains to be determined. Biomarkers
linked to effects on these non-amyloid aspects of AD
biology might eventually be shown to be reasonably
likely to predict clinical benefit and be employed in future
accelerated approval strategies.
Accelerated approval is intended to make drugs
available to patients with life-threatening diseases such
as AD while additional evidence to confirm efficacy
and safety is generated. The decision of CMS to limit
aducanumab to clinical trials is at variance with the
purpose of this approach and inconsistent with the intent
of the FDA to provide a mechanism for accelerated access
to aducanumab for appropriate patients.

Accelerated Approval
Aducanumab was approved by the FDA using the
regulatory mechanism of accelerated approval. This
approval pathway was used for 14 of 50 (28%) approvals
by the FDA in 2021 and is commonly used for cancer
therapies (9). Accelerated approval is employed when
a potential treatment for a life-threatening illness has an
effect on a surrogate endpoint that is reasonably likely to
predict clinical benefit (10). Post-marketing confirmatory
trials may be required to verify the anticipated effect.
Uncertainty about whether clinical benefit will be
verified, and the possibility of undiscovered risks are the
primary reasons that accelerated approval is reserved
for drugs intended to treat serious conditions. As
described by the FDA, determining whether an endpoint
is reasonably likely to predict clinical benefit is a matter of
judgment that will depend on the biological plausibility
of the relationship between the disease and the endpoint
and the empirical evidence supporting that relationship.
The FDA guidance on accelerated approval notes that
this regulatory mechanism is consistent with the agency’s
commitment to flexibility regarding the evidence required
to support product approval for the treatment of serious
or life-threatening diseases with limited therapeutic
options (10). There are provisions for withdrawal of
approval if post-approval trials fail to verify the predicted
clinical advantages. A confirmatory trial of aducanumab
is required and approval can be retracted if efficacy is not
supported.
Reduction of amyloid plaques as shown on amyloid
PET is the biomarker on which accelerated approval was
based. Plaque reduction is not a fully validated surrogate
and there is a lack of consensus on the predictive value
of plaque removal. There have been many failures of
anti-amyloid therapies suggesting that approval based
on anti-amyloid effects does not have an adequate
scientific rationale (11). Nearly all the failed programs
have been directed at pre-plaque species of Aβ and did
not decrease amyloid plaques. Plaques have been linked
by many observations to cognitive impairment in AD,
and the effect of mAbs on plaques meets the standard
of “reasonably likely” to predict clinical benefit (8, 12).
Two other sponsors of mAb development programs are
pursuing accelerated approval based on plaque lowering
effects (Eisai for lecanemab and Eli Lilly for donanemab);
both mAbs have shown preliminary evidence of slowing
of clinical decline in addition to the biomarker efficacy
(13, 14). To what extent plaque removal is the critical

CMS Draft Decision
In their draft determination, CMS proposed to cover
FDA approved mAbs directed against plaque amyloid
for the treatment of AD under a Coverage with Evidence
Development (CED) approach limiting coverage of mAbs
to patients participating in CMS-approved randomized
controlled trials supported by the NIH (3). All trials
must be conducted in a hospital-based outpatient setting.
Based on the lack of inclusion of underserved populations
in past trials, CMS requires enrollment of a patient
population representative of those diagnosed with AD.
The CMS draft proposal addresses anti-amyloid mAbs as
a class.
This approach is not patient-centered and will greatly
delay access to treatment for individuals with early AD.
This proposed determination is predicted to reduce
interest in treatment development when the increasing
population of those with and at risk for AD requires
innovative solutions for their cognitive and functional
impairment.

Controlled Clinical Trials
Requiring that aducanumab be studied in clinical trials
conducted in a hospital setting greatly limits the number
of patients with early AD who could receive treatment
with coverage. Proposed trials are likely to be placebocontrolled (not explicitly required in the proposed
decision memo but implied by the trial requirements).
In placebo-controlled trials, patients seeking treatment
must agree to be randomized to drug or placebo to have a
chance of receiving therapy. Severely limiting access to an
approved therapy in this way is coercive.
Requiring that the trial be funded by NIH attaches
additional limits to the availability of treatment. NIH
funding is directed mostly to trial sites associated with
academic medical centers restricting access to therapy
to those living in nearby areas. Academic trials sites are
rarely in minority neighborhoods and are not situated
to allow recruitment of rural populations (also under3
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represented in clinical trials). NIH funding for trials is
less than that invested by pharmaceutical companies
and recruiting an adequate number of participants to
adequately power a trial to demonstrate benefit may be
difficult if not impossible. Funding by NIH is subject to
extensive peer review on scheduled review cycles. Trials
as proposed by CMS would require 1-2 years to secure
funding plus 3-5 years to conduct and analyze, delaying
the availability of an approved treatment that could be
available NOW. NIH funding has been instrumental in
supporting Phase 2 proof-of-concept and dose-finding
studies; it has rarely been used for trials of the type
proposed by CMS that more closely resemble Phase 3
trials (15).
CMS requires that approved trials must determine
if treatment with an anti-amyloid mAb results in
a statistically significant and meaningful reduction in
decline in cognition and function. CMS chose the CDRSB to exemplify what constitutes a clinically meaningful
improvement as a primary outcome. To define minimal
clinically important differences they suggest a 1-2
point increase in CDR-SB, plus a 1-3 point decrease in
MMSE and 3-5 point increase in Functional Activities
Questionnaire (FAQ) (16). The population from which
these figures were derived is a biologically unconfirmed
non-trial population with data contributed to the US
National Alzheimer Coordinating Center; these patients
differ substantially from those to be included in CMSapproved trials of patients with early AD confirmed
by positive amyloid imaging and healthy enough to
participate in a trial. No means of translating outcomes
on these tools to the stated purpose of the trials to
demonstrate “meaningful improvement in health
outcomes” is provided.
The CMS proposal does not state how many trials
with meaningful results are required to support coverage
although the proposed decision memo refers to “trials.”
The expected relationship of results from different trials
or the required consistency of outcomes is not discussed.
Noting the lack of diversity in previous trials, the
higher prevalence of AD in Black and non-White
Americans, and the directives in Executive Order 13985,
Advancing Racial Equity and Support for Underserved
Communities through the Federal Government, CMS
proposes requiring that the patients included in each
trial be representative of the national population
diagnosed with AD. This is a noble aspiration. It is also
an unrealistic expectation given the known challenges
in recruiting underrepresented and underserved
populations to trials. We must improve inclusion of
diverse populations in trials; this is a long-term goal
requiring trial infrastructure not currently available and
trust that has not been built. Requiring a representative
sample in the CMS trial will delay the trial and limit
the availability of drug treatment to both minority and
majority culture patients. The mandate ignores other
underserved populations such as those dwelling in rural

areas who have essentially no opportunity to reach trial
sites and treatment in a trial.
Aducanumab is approved and can be purchased
through self-pay mechanisms independent of coverage by
CMS. Limitation of treatment coverage to those in trials
means that persons in limited financial circumstances will
have limited access to therapy while those with financial
means will have access to treatment. CMS requirements
will increase the lack of equity in AD care in the US.
Unlike participating in an industry-sponsored trial
where experimental therapy is provided without cost,
CMS typically does not cover the full costs of drugs
and a substantial co-payment may be leveraged for
aducanumab trial participants. Up to 50 percent of
patients in a trial (depending on the use of a placebo
and the randomization ratio) may be paying for placebo.
These circumstances will further disincentivize trial
participation.
Together these observations argue against the
requirement for a CED comprised of clinical trials to
provide coverage for mAbs.

Real World Use
CMS expresses concerns about harms to patients
that would be treated outside the context of the safety
monitoring of a controlled trial. Clinicians agree that
the occurrence of ARIA can have serious consequences
and must be monitored. In the EMERGE and ENGAGE
trials, most ARIA events (72.3%) occurred within the
period of the first eight doses (7 months) and vigilance
early in the course of therapy is key to safe introduction
of aducanumab. Seventy-four percent of those with
MRI-proven ARIA had no symptoms. Of the 26 percent
who exhibited symptoms, most had headache with fewer
having confusion, dizziness, or nausea (7). A few patients
have severe symptoms including seizures, and one death
has occurred a patient with a complex medical history
and ARIA. The risks of ARIA do not exceed those of
cancer therapies that are routinely covered by CMS;
limitation of coverage for treatment of patients with AD is
disease-based discrimination.
To assist clinicians in real world settings with the
management of ARIA, an Expert Panel developed
Appropriate Use Recommendations that describe the
baseline magnetic resonance imaging (MRI) findings
suggesting the patient may not be a good candidate for
aducanumab, provide guidance for optimal timing of
MRI to detect ARIA, and discuss ARIA management
strategies when the MRI changes of ARIA are
detected (17). As real-world experience is gained with
aducanumab and other mAbs, use recommendations
will be adjusted to ensure patient safety and optimize the
opportunity for efficacy.
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Monoclonal Antibodies as a Class

Summary and Call to Action

Monoclonal antibodies directed at amyloid plaques
are the first agents to show an effect on the underlying
biology of AD and to qualify as disease-modifying
therapies. These agents have succeeded where many
non-plaque-directed anti-amyloid therapies have failed
(11). They present new requirements for patient diagnosis
and monitoring including diagnostic biomarkers,
genotyping, and safety assessments. They represent
a breakthrough class of drugs that can initiate a new
era in AD therapeutics. We are at the beginning of this
era and only one agent (aducanumab) has completed
Phase 3 trials. There are promising data emerging from
trials of plaque-lowing mAbs including donanemab,
lecanemab, and gantenerumab (13, 14, 18). These agents
have different delivery approaches, dosing strategies,
titration schedules, and target epitopes. Preliminary
observations suggest that they may have different rates
of ARIA, and comparative efficacy is unknown. It is
premature to suggest that a CED will be required for all
plaque lowering mAbs.
Not all anti-amyloid mAbs are plaque-lowering.
Solanezumab is directed at the monomeric form of
Aß. It does not lower plaque burden. A Phase 3 trial in
mild AD dementia did not meet its primary outcome;
it is uncertain if limited efficacy was shown (19). This
mAb is very different than plaque-lowering mAbs and
approaching anti-amyloid mAbs as a group does not
recognize this diversity.

CMS concludes the proposed decision memo by
stating that the proposal strikes an appropriate balance
of providing patient access while also ensuring both
protections for patients from harms and the appropriate
data collection and analysis to determine whether CMS
should undertake an NCD reconsideration (3). The
recommended decision does not strike an appropriate
balance. Evidence of efficacy is discounted; evidence of
harm is exaggerated; the purpose of accelerated approval
to make drugs available while data are generated is
ignored; the requirement for confirmatory trials funded
by NIH and conducted in hospital settings creates
undue delay; the discussion of primary trial outcomes
and minimal important differences is premature and the
data are extrapolated from non-trial populations; the
desire for proportional representation of underserved
minorities in trial populations is laudable but impractical
as proposed and will increase treatment inequities; the
availability of aducanumab to those who can pay for it
and accessible only through trials for those who cannot
afford it is improper; application of the CED requirement
to all anti-amyloid mAbs is inappropriate and will
stifle innovation. These issues should be addressed
in a revised proposal. Alternative approaches such as
registries, collection of real world evidence, examination
of claims data, and post-marketing studies should be
entertained. The Proposed Decision Memo is open to
public comment (closing 30 days from January 11, 2022).
Motivated individuals can submit comments on the CMS.
gov website (https://www.cms.gov/medicare-coveragedatabase/search.aspx).

Effect on Innovation
Drug development for AD is a costly and lengthy
enterprise requiring extensive financial and time
investment (Figure 1). Pharmaceutical and biotechnology
companies must realize a return on investment to warrant
committing resources to a therapeutic area. Delaying
a return on mAb development costs while a CED is
conducted will disincentivize drug development for
AD. The balance between encouraging innovation with
financial incentives while not unduly escalating drug
prices is difficult to achieve and is a topic of national and
international dialogue (20). Finding the right balance
between innovation and drug costs will be a catalyst to
developing treatments urgently needed for patients with
AD. Reimbursement models such as that developed for
aducanumab by the Institute for Clinical and Economic
Review (ICER) --- on which CMS depended in part for
the proposed coverage decision --- have no terms in their
formulae for innovation and adopt primarily a health care
systems perspective (21). These models provide insights
but are not balanced multi-stakeholder views.
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